Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

Schisandrol B

Copy Product Info
😃Good
Catalog No. T6S1917Cas No. 58546-54-6
Alias Wuweizi alcohol-B, TJN-101, Schizandrol B, Gomisin A, Gamma-Schisandrin, Besigomsin

1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. 2. Schisandrol B has anti-inflammatory property, potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. 3. Schisandrol B induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. 4. Schisandrol B significantly inhibits cell proliferation in a dose-dependent manner, due to cell cycle arrest in the G1 phase with the downregulation of cyclin D1 expression and Retinoblastoma (RB) phosphorylation.

Schisandrol B
Other Forms of Schisandrol B:

Schisandrol B

Copy Product Info
😃Good
Purity: 99.95%
Catalog No. T6S1917Alias Wuweizi alcohol-B, TJN-101, Schizandrol B, Gomisin A, Gamma-Schisandrin, BesigomsinCas No. 58546-54-6
1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. 2. Schisandrol B has anti-inflammatory property, potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. 3. Schisandrol B induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. 4. Schisandrol B significantly inhibits cell proliferation in a dose-dependent manner, due to cell cycle arrest in the G1 phase with the downregulation of cyclin D1 expression and Retinoblastoma (RB) phosphorylation.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mg$65In StockIn Stock
10 mg$97In StockIn Stock
25 mg$212In StockIn Stock
50 mg$318In StockIn Stock
100 mg$476In StockIn Stock
500 mg$1,090-In Stock
1 mL x 10 mM (in DMSO)$72In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.95%
Color:White
Contact us for more batch information

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity
Description
1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. 2. Schisandrol B has anti-inflammatory property, potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. 3. Schisandrol B induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. 4. Schisandrol B significantly inhibits cell proliferation in a dose-dependent manner, due to cell cycle arrest in the G1 phase with the downregulation of cyclin D1 expression and Retinoblastoma (RB) phosphorylation.
SynonymsWuweizi alcohol-B, TJN-101, Schizandrol B, Gomisin A, Gamma-Schisandrin, Besigomsin
Chemical Properties
Molecular Weight416.46
FormulaC23H28O7
Cas No.58546-54-6
SmilesCOc1cc2CC(C)(O)C(C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC
Relative Density.1.21g/cm3
Storage & Solubility Information
Storagekeep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 245 mg/mL (588.29 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.8 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4012 mL12.0060 mL24.0119 mL120.0595 mL
5 mM0.4802 mL2.4012 mL4.8024 mL24.0119 mL
10 mM0.2401 mL1.2006 mL2.4012 mL12.0060 mL
20 mM0.1201 mL0.6003 mL1.2006 mL6.0030 mL
50 mM0.0480 mL0.2401 mL0.4802 mL2.4012 mL
100 mM0.0240 mL0.1201 mL0.2401 mL1.2006 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

TJN101TJN 101Schisandrol BReactiveOxygenSpeciesReactive Oxygen SpeciesP-glycoproteinPCNAp53p21lignanInhibitorinhibitHepato-protectiveGomisin-ACytochrome P450CYPsCYP3A11CYP2E1CCND1BCL-2Autophagyantioxidantanti-inflammatoryanti-diabetic
Related Tags: buy Schisandrol B | purchase Schisandrol B | Schisandrol B cost | order Schisandrol B | Schisandrol B chemical structure | Schisandrol B formula | Schisandrol B molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.